New UCLA Study Shows AtheroNova’s AHRO-001 Targets Much More than Cholesterol
Metabolic Syndrome (“MS”) affects approximately a quarter of the U.S. population, according to a 2002 National Health and Nutrition Examination Survey. Characterized by raised triglycerides, reduced HDL cholesterol, high BMI/waistline, raised blood pressure, and raised fasting plasma glucose, the syndrome significantly increases the risk of heart disease and a host of other health problems, including stroke, diabetes and some common forms of cancer.
Savvy readers may be surprised that LDL cholesterol is absent from the list, despite the fact that the media has demonized cholesterol. Meanwhile, companies like Pfizer Inc. (NYSE: PFE), Merck & Co. (NYSE: MRK) and AstraZeneca plc (NYSE: AZN) have all built multi-billion dollar statin drugs designed specifically to reduce LDL cholesterol. In reality, a broader approach may be necessary and these statins may need to be supplemented with additional drugs.
While statins produced by these companies have been shown to modestly raise HDL cholesterol levels, investors may want to take a look at a newer company with a compound that has the potential to address multiple aspects of Metabolic Syndrome. AtheroNova Inc.’s (OTCQB: AHRO) AHRO-001 uses natural bile salts to reduce several metabolic syndrome factors as well as possible regression of atherosclerosis by lowering fasting plasma glucose levels, reducing cholesterol absorption, and improving HDL cholesterol function.
Taking a Natural Approach
AtheroNova recently announced preclinical study results outlining the potential of AHRO-001 in the FASEB Journal – one of the world’s most cited biology journals. The pre-clinical study, entitled Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice – examined the effects of AHRO-001’s active ingredient – hyodeoxycholic acid – on lipid metabolism and atherosclerosis in LDL receptor-null (“LDLRKO”) lab mic